STAT+: Pharmalittle: Biotech CEOs pull in some of health care’s biggest paydays; split emerges between groups providing abortion pills

When it comes to executive compensation in the biotech and pharma sectors, it pays to be the CEO at Regeneron Pharmaceuticals.

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that predictable routine of online calls, meetings, and deadlines has, of course, returned. But you know the drill — the world keeps spinning, so find a way to remain on board. We do this by quaffing cups of stimulation and our choice today is the ever-so-sweet glazed doughnuts. Yes, this is a real flavor. So time to get cracking. Here is the latest laundry list of interesting items to help you on your own journey. We hope you have a meaningful and productive day. And please do keep in touch. Even in this day and age, postcards and telegrams are useful. …

When it comes to executive compensation in the biotech and pharma sectors, it pays to be the chief executive officer at Regeneron Pharmaceuticals, STAT tells us. Len Schleifer, took home $453 million in 2021, more than any other executive in the sector, which represents just less than the entire combined compensation — $478 million — of the next nine highest-paid chief executive officers. In addition to salary, cash-based bonuses, and other perks, total compensation was calculated by using the “actual realized gains” of stock options and awards, instead of the estimated fair value of those options and awards that is more commonly reported.

Continue to STAT+ to read the full story…